Retrospective cohort study shows GLP-1 receptor agonists improve exercise activity and outcomes in multiple sclerosis, suggesting beneficial effects.
To assess whether initiation of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) was associated with changes in exercise activity and patient-reported outcomes (PROs) in people with multiple sclerosis (MS).
No takes yet. Share an insight, caveat, or question.
Heward et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: